
Patrick Trucchio
Stock Analyst at H.C. Wainwright
(4.84)
# 442
Out of 5,136 analysts
1190
Total ratings
43.8%
Success rate
19.5%
Average return
Main Sectors:
Stocks Rated by Patrick Trucchio
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGMB AgomAb Therapeutics NV | Reiterated: Buy | $35 | $5.97 | +486.26% | 8 | Nov 16, 2026 | |
| FTH Faeth Therapeutics | Reiterated: Buy | $60 | $9.28 | +546.55% | 9 | Nov 16, 2026 | |
| GOSS Gossamer Bio | Reiterated: Buy | $90 | $10.98 | +719.67% | 53 | Nov 16, 2026 | |
| VYGR Voyager Therapeutics | Reiterated: Buy | $25 | $1.63 | +1,433.74% | 33 | Nov 16, 2026 | |
| ANRO Alto Neuroscience | Reiterated: Buy | $60 | $27.12 | +121.24% | 24 | Nov 12, 2026 | |
| HRMY Harmony Biosciences Holdings | Reiterated: Buy | $55 | $32.96 | +66.87% | 32 | Nov 12, 2026 | |
| ONCY Oncolytics Biotech | Reiterated: Buy | $5 | $0.3399 | +1,371.02% | 54 | Nov 12, 2026 | |
| ALGS Aligos Therapeutics | Reiterated: Buy | $50 | $1.66 | +2,912.05% | 25 | Nov 11, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $455 | $159.73 | +184.86% | 82 | Nov 11, 2026 | |
| ALT Altimmune | Reiterated: Buy | $20 | $1.56 | +1,182.05% | 52 | Nov 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 | $44.21 | +171.43% | 77 | Nov 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $21.29 | +134.85% | 20 | Nov 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 | $20.94 | +282.04% | 34 | Nov 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $7.28 | +724.18% | 70 | Nov 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $100 → $80 | $28.88 | +177.01% | 57 | Nov 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 | $9.58 | +129.65% | 72 | Nov 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $65 | $8.27 | +685.97% | 63 | Nov 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 | $30.16 | +132.10% | 47 | Nov 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $65 | $18.75 | +246.67% | 41 | Nov 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $2.15 | +1,993.02% | 16 | Nov 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 | $21.88 | +265.63% | 65 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $145 | $22.61 | +541.31% | 17 | Nov 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $75 → $20 | $19.80 | +1.01% | 45 | Oct 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $32.44 | +84.96% | 13 | Oct 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $0.5377 | +1,759.77% | 42 | Sep 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $0.8286 | +1,106.85% | 9 | Sep 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.1089 | - | 51 | Jun 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $10 | $0.365 | n/a | 34 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $360 | $8.29 | n/a | 14 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $8.54 | n/a | 5 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.05 | n/a | 5 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 100p → 46p | 1p | n/a | 3 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €33.00 | €2.94 | n/a | 10 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 → $130 | $10.67 | n/a | 3 | Sep 18, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $117 → $72 | $16.18 | n/a | 2 | Nov 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $22 | $18.49 | n/a | 1 | Apr 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $25 | $4.85 | n/a | 1 | Apr 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $125 | $111.34 | n/a | 1 | Dec 23, 2014 |
AgomAb Therapeutics NV
Nov 16, 2026
Reiterated: Buy
Price Target: $35
Current: $5.97
Upside: +486.26%
Faeth Therapeutics
Nov 16, 2026
Reiterated: Buy
Price Target: $60
Current: $9.28
Upside: +546.55%
Gossamer Bio
Nov 16, 2026
Reiterated: Buy
Price Target: $90
Current: $10.98
Upside: +719.67%
Voyager Therapeutics
Nov 16, 2026
Reiterated: Buy
Price Target: $25
Current: $1.63
Upside: +1,433.74%
Alto Neuroscience
Nov 12, 2026
Reiterated: Buy
Price Target: $60
Current: $27.12
Upside: +121.24%
Harmony Biosciences Holdings
Nov 12, 2026
Reiterated: Buy
Price Target: $55
Current: $32.96
Upside: +66.87%
Oncolytics Biotech
Nov 12, 2026
Reiterated: Buy
Price Target: $5
Current: $0.3399
Upside: +1,371.02%
Aligos Therapeutics
Nov 11, 2026
Reiterated: Buy
Price Target: $50
Current: $1.66
Upside: +2,912.05%
Alnylam Pharmaceuticals
Nov 11, 2026
Reiterated: Buy
Price Target: $455
Current: $159.73
Upside: +184.86%
Altimmune
Nov 11, 2026
Reiterated: Buy
Price Target: $20
Current: $1.56
Upside: +1,182.05%
Nov 11, 2026
Reiterated: Buy
Price Target: $120
Current: $44.21
Upside: +171.43%
Nov 11, 2026
Reiterated: Buy
Price Target: $50
Current: $21.29
Upside: +134.85%
Nov 11, 2026
Reiterated: Buy
Price Target: $80
Current: $20.94
Upside: +282.04%
Nov 10, 2026
Reiterated: Buy
Price Target: $60
Current: $7.28
Upside: +724.18%
Nov 10, 2026
Reiterated: Buy
Price Target: $100 → $80
Current: $28.88
Upside: +177.01%
Nov 10, 2026
Reiterated: Buy
Price Target: $22
Current: $9.58
Upside: +129.65%
Nov 9, 2026
Reiterated: Buy
Price Target: $65
Current: $8.27
Upside: +685.97%
Nov 9, 2026
Reiterated: Buy
Price Target: $70
Current: $30.16
Upside: +132.10%
Nov 9, 2026
Reiterated: Buy
Price Target: $65
Current: $18.75
Upside: +246.67%
Nov 9, 2026
Reiterated: Buy
Price Target: $45
Current: $2.15
Upside: +1,993.02%
Nov 5, 2026
Reiterated: Buy
Price Target: $80
Current: $21.88
Upside: +265.63%
Nov 2, 2026
Reiterated: Buy
Price Target: $145
Current: $22.61
Upside: +541.31%
Oct 21, 2026
Downgraded: Hold
Price Target: $75 → $20
Current: $19.80
Upside: +1.01%
Oct 6, 2026
Reiterated: Buy
Price Target: $60
Current: $32.44
Upside: +84.96%
Sep 30, 2026
Reiterated: Buy
Price Target: $10
Current: $0.5377
Upside: +1,759.77%
Sep 21, 2026
Reiterated: Buy
Price Target: $10
Current: $0.8286
Upside: +1,106.85%
Jun 9, 2026
Rated: Hold
Price Target: n/a
Current: $0.1089
Upside: -
Apr 2, 2025
Reiterated: Buy
Price Target: $25 → $10
Current: $0.365
Upside: n/a
May 15, 2023
Reiterated: Buy
Price Target: $20 → $360
Current: $8.29
Upside: n/a
Feb 10, 2023
Rated: Hold
Price Target: n/a
Current: $8.54
Upside: n/a
Feb 10, 2023
Rated: Hold
Price Target: n/a
Current: $0.05
Upside: n/a
Nov 2, 2022
Reiterated: Buy
Price Target: 100p → 46p
Current: 1p
Upside: n/a
Mar 27, 2020
Reiterated: Buy
Price Target: €33.00
Current: €2.94
Upside: n/a
Sep 18, 2019
Reiterated: Buy
Price Target: $120 → $130
Current: $10.67
Upside: n/a
Nov 13, 2018
Downgraded: Hold
Price Target: $117 → $72
Current: $16.18
Upside: n/a
Apr 19, 2018
Initiated Coverage: Buy
Price Target: $22
Current: $18.49
Upside: n/a
Apr 19, 2018
Initiated Coverage: Buy
Price Target: $25
Current: $4.85
Upside: n/a
Dec 23, 2014
Upgraded: Buy
Price Target: $125
Current: $111.34
Upside: n/a